Literature DB >> 15605215

[Diagnosis of the antiphospholipid syndrome in anticoagulated patients].

M Mohren1, T Daikeler, A Engel, I Guenaydin, I Koetter.   

Abstract

The antiphospholipid syndrome is characterized by thromboembolic events and/or recurrent miscarriages in the presence of anticardiolipin antibodies and/or a lupus anticoagulant. Anticardiolipin antibodies are detected by ELISA whereas lupus anticoagulant detection includes a variety of coagulometric tests. However, a large number of patients with suspected antiphospholipid syndrome are anticoagulated with either heparin or coumadin when evaluated for the presence of a lupus anticoagulant and false positive test results may ensue, thus making coagulometric testing unreliable in this situation. Modifications of standard coagulometric tests have been suggested in order to circumvent this problem and studies of several patient cohorts have shown that the majority of patients with the antiphospholipid syndrome are anticardiolipin positive. However diagnosis in patients receiving anticoagulation remains a difficult task.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605215     DOI: 10.1007/s00393-004-0593-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  23 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

Review 2.  Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome.

Authors:  Monica Galli; Davide Luciani; Guido Bertolini; Tiziano Barbui
Journal:  Blood       Date:  2003-06-19       Impact factor: 22.113

3.  Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome.

Authors:  A S Lawrie; G Purdy; I J Mackie; S J Machin
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

4.  Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants.

Authors:  T Exner; D A Triplett; D Taberner; S J Machin
Journal:  Thromb Haemost       Date:  1991-03-04       Impact factor: 5.249

5.  The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level.

Authors:  M Petri; M Rheinschmidt; Q Whiting-O'Keefe; D Hellmann; L Corash
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

6.  Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH.

Authors:  J T Brandt; L K Barna; D A Triplett
Journal:  Thromb Haemost       Date:  1995-12       Impact factor: 5.249

7.  Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins.

Authors:  A Tripodi; V Chantarangkul; M Clerici; B Negri; M Galli; P M Mannucci
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

8.  Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.

Authors:  D A Horbach; E van Oort; R C Donders; R H Derksen; P G de Groot
Journal:  Thromb Haemost       Date:  1996-12       Impact factor: 5.249

9.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

10.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.